Skip to main content

Viread News

Exposure to Certain HIV Drugs May Significantly Lower Risk for Alzheimer Disease

TUESDAY, May 20, 2025 – Exposure to nucleoside reverse transcriptase inhibitors (NRTIs), which treat HIV and hepatitis B and inhibit inflammasome activation, is associated with a significantly lower...

Key HIV Care Teams Let Go, Putting Mothers and Children at Risk

WEDNESDAY, April 9, 2025 – The Trump administration has let go of the last remaining U.S. health officials who oversaw HIV care for more than 1.1 million mothers and children in low-income...

Preexposure Prophylaxis Use for HIV Increased in Recent Years

MONDAY, Oct. 21, 2024 – Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 in the Journal of the American Medical ...

FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...

FDA Approves Gilead’s Vemlidy (tenofovir alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 10, 2016-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Vemlidy (tenofovir...

FDA Approves Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) for HIV

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for...

U.S. Food and Drug Administration Approves New Formulations of Viread for Use by Children Living With HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Jan 19, 2012 - Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Viread (tenofovir disoproxil fumarate) in...

FDA Medwatch Alert: Viread (tenofovir disoproxil fumarate)

Gilead Sciences, Inc. notified healthcare professionals of a high rate of early virologic failure and emergence of nucleoside reverse transcriptase inhibitor (NRTI) resistance associated mutations...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

HIV Infection

Viread patient information at Drugs.com